2025-521921-34-00
尚未招募
1 期
A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin
概览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 32
- 试验地点
- 1
概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
US Program Manager Product Development Regulatory
Scientific
Genentech Inc.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase I Study of RO7589831 Alone and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors2023-503170-20-01F. Hoffmann-La Roche AG46
尚未招募
1 期
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity2025-521401-41-00F. Hoffmann-La Roche AG30
已完成
1 期
A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.2023-506564-14-00Celgene International II S.a.r.l.112
尚未招募
1 期
First-in-Human Study of RO78126532025-522101-37-00F. Hoffmann-La Roche AG12
已完成
1 期
A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human body.2023-506114-49-00Cerevance Inc.64